World Markets for Novel Vaccine Delivery Devices, 2019-2030: Analysis by Type of Device, Route of Administration, Type of Vaccine, and Key Geographical Region - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 3, 2020--
The “Novel Vaccine Delivery Devices Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering.
Novel Vaccine Delivery Devices Market, 2019-2030 features an extensive study of the current landscape and the likely future opportunities associated with novel vaccine delivery devices, over the next 10-12 years.
One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for novel vaccine delivery devices. Based on various parameters, such as number of marketed / pipeline products, price of devices (for commercially available products only) and estimated annual adoption rate, we have developed an informed estimate on the likely evolution of the market over the period 2019-2030.
In addition, we have provided the likely distribution of the current and forecasted opportunities across:
According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025.
Recent global immunization records indicate that more than 115 million children were immunized against diphtheria, tetanus and pertussis in 2018. Given the rate at which the global population is growing, the demand for vaccines is likely to increase significantly.
However, biopharmaceutical developers are plagued by concerns related to storage and handling of such preventive / therapeutic products. One commonly reported issue is related to vaccine administration. Despite the success of conventional delivery approaches, which rely on the intramuscular and subcutaneous routes of administration, the present scenario dictates that further improvements are required in order to deal with challenges related to large scale immunization initiatives. Some of the commonly reported disadvantages of the conventional (parenteral) mode of delivery include pain during administration, risk of cross contamination, needlestick injuries, and inaccurate dosing.
Of late, there has been an evident shift in interest to non-invasive immunization methods, which include oral, intranasal and transdermal modes of administration. Currently, many biopharmaceutical companies and clinical research institutes are engaged in the development of novel vaccine delivery systems, taking into consideration the specific requirements of large scale immunization initiatives. As a result, significant efforts have been put into the development of drug delivery technologies / devices, such as microneedle patches, electroporation-based needle free injection systems, jet injectors, inhalation-based delivery systems, biodegradable implants and certain novel types of oral delivery systems.
It is worth highlighting that most of the aforementioned systems are specifically being designed to facilitate pain-free administration of vaccines and allow self-administration. Vaccine developers are also attempting to devise ways to make such products more stable so as to eliminate the need for cold chain in transporting such products. Given the pace of innovation in this field, it is anticipated that the novel vaccine delivery devices market is likely to witness radical changes in the coming years.
Amongst other elements, the report includes:
In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.
The report features detailed transcripts of interviews held with the following industry stakeholders:
Key Topics Covered
2. Executive Summary
4. Market Landscape
5. Device Competitiveness Analysis
6. Technology Effectiveness Analysis
7. Novel Vaccine Delivery Devices: Likely Vaccine Candidates
8. Company Profiles
9. Partnerships and Collaborations
10. SWOT Analysis
11. Market Sizing and Opportunity Analysis
12. Executive Insights
13. Concluding Remarks
14. Appendix 1: Tabulated Data
15. Appendix 2: List of Companies and Organizations
For more information about this report visit https://www.researchandmarkets.com/r/tvxdn1
View source version on businesswire.com:https://www.businesswire.com/news/home/20200103005253/en/
Laura Wood, Senior Press Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 01/03/2020 10:27 AM/DISC: 01/03/2020 10:27 AM